<DOC>
	<DOCNO>NCT01442246</DOCNO>
	<brief_summary>PRINCIPAL OBJECTIVE : Evaluation effectiveness term survival without metastasis 10 year , adjuvant hormonal treatment leuprorelin acetate ( Eligard® 45 mg ) 24 month radical prostatectomy patient high risk recurrence . SECONDARY OBJECTIVE ( S ) : - PSA evolution - Evaluation testosterone level - Specific survival - Overall survival - Tolerance - Quality life ( QLQ-C30 questionnaire )</brief_summary>
	<brief_title>Evaluation Adjuvant Hormonal Treatment 24 Months After Radical Prostatectomy High Risk Recurrence Patients .</brief_title>
	<detailed_description />
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . Patients receive information leaflet sign consent form 2 . ≥ 18 year age life expectancy least 10 year 3 . Performance Status ( ECOG ) ≤ 2 4 . Radical prostatectomy ( RP ) without extend pelvic lymphadenectomy 3 month precede inclusion 5 . Histologically confirm prostatic adenocarcinoma 6.6 . Patients R0 , N0 Nx N+ ( ≤ 2 node among node remove ) , M0 least one follow criterion : postoperative Gleason score &gt; 7 ; postoperative Gleason score = 7 presence highgrade Gleason pattern ( 5 ) ; pT3b patient . 7.Postoperative PSA &lt; 0.1 ng/mL ( dosage perform within 2 month surgery ) 8.Neutrophils ≥ 1500/mm3 , platelet ≥ 100000/mm3 9.Bilirubin ≤ upper normal limit ( apply subject Gilbert 's syndrome , persistent recurrent hyperbilirubinemia predominantly uncongugated absence evidence hemolysis hepatic pathology ) ; ASAT ALAT ≤ 1.5 time upper normal limit ; Creatinine &lt; 140 µmol/l ( clearance &gt; 60mL/min ) 10.Patients affiliated social security scheme 1 . Previous treatment prostatic adenocarcinoma ( HT orchyectomy CT ) 2 . Presence metastasis : positive bone scintigraphy , include Patients medullary compression and/or abdominalpelvic CT scan MRI show lymph node and/or visceral involvement . 3 . History cancer , exception basal cell carcinoma cancer treat 5 year inclusion complete remission . 4 . Incompatible concomitant treatment ( ) 5 . Hypersensitivity GnRH agonists and/or excipients Eligard® 6 . Any illness problem include geographic , psychiatric psychological incompatible monitor trial 7 . Persons deprive freedom supervision ( include guardianship ) , 8 . Patients already include another therapeutic trial experimental drug give experimental drug within period 30 day .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Benefit</keyword>
	<keyword>adjuvant</keyword>
	<keyword>treatment</keyword>
	<keyword>prostatectomy</keyword>
</DOC>